Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.84 |
| ▸ | RARB | P10826 | 5/20 | 0.82 |
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | PLA2G4B | P0C869 | 7/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10535685 | 0.93 | RARB (0.88) | MAPK1RARBTSHRTP53PLA2G4B | |
| SCHEMBL10535460 | 0.93 | RARB (0.88) | MAPK1RARBTSHRTP53PLA2G4B | |
| SCHEMBL10537317 | 0.93 | RARB (0.88) | MAPK1RARBTSHRTP53PLA2G4B | |
| SCHEMBL10334195 | 0.93 | RARB (0.88) | MAPK1RARBTSHRTP53PLA2G4B | |
| SCHEMBL9813425 | 0.93 | RARB (0.88) | MAPK1RARBTSHRTP53PLA2G4B | |
| SCHEMBL6538723 | 0.91 | MAPK1 (1.00) | MAPK1RARBTSHRTP53PLA2G4B | |
| SCHEMBL4181436 | 0.91 | RARB (1.00) | MAPK1RARBTSHRTP53PLA2G4B | |
| SCHEMBL28520501 | 0.89 | MAPK1 (0.77) | MAPK1RARBTSHRTP53PLA2G4B | |
| SCHEMBL15449670 | 0.89 | MAPK1 (0.77) | MAPK1RARBTSHRTP53PLA2G4B | |
| SCHEMBL10785289 | 0.89 | MAPK1 (0.77) | MAPK1RARBTSHRTP53PLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6812235-B2 | 2-ACYLAMINO- BETA -ALANINE DERIVATIVES AND A PHARMACEUTICALLY ACCEPTABLE SALT, USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-02 | — | — | US | disclosed |
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ASTELLAS PHARMA INC. (JP) | 2003-01-23 | — | — | US | disclosed |
| EP-1255748-A1 | BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001060813-A1 | BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-23 | — | — | WO | disclosed |
| US-6008401-A | CONDENSATION REACTION BETWEEN 4-HALO OR NITRO SUBSTITUTED BENZONITRILE DERIVATIVE AND OTICALLY ACTIVE ALCOHOL PRODUCES AN OPTICALLY ACTIVE ALKOXYBENZONITRILE DERIVATIVE | NIPPON OIL CO., LTD. (JP) | 1999-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ARRB1, ADRB1, GLRB | MAPK1 1483/4885RARB 322/4885TSHR 689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.